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Abstract
Background: Efficiency and efficacy of organised mammography screening programs have been proven in large
randomised trials. But every local implementation of mammography screening has to check whether the well
established quality standards are met. Therefore it was the aim of this study to analyse the most common quality
indices after introducing organised mammography screening in Tyrol, Austria, in a smooth transition from the
existing system of opportunistic screening.
Methods: In June 2007, the system of opportunistic mammography screening in Tyrol was changed to an
organised system by introducing a personal invitation system, a training program, a quality assurance program and
by setting up a screening database. All procedures are noted in a written protocol. Most EU recommendations for
organised mammography screening were followed, except double reading. All women living in Tyrol and covered
by social insurance are now invited for a mammography, in age group 40-59 annually and in age group 60-69
biannually. Screening mammography is offered mainly by radiologists in private practice. We report on the results
of the first year of piloting organised mammography screening in two counties in Tyrol.
Results: 56,432 women were invited. Estimated participation rate was 34.5% at one year of follow-up (and
55.5% at the second year of follow-up); 3.4% of screened women were recalled for further assessment or
intermediate screening within six months. Per 1000 mammograms nine biopsies were performed and four
breast cancer cases detected (N = 68). Of invasive breast cancer cases 34.4% were ≤ 10 mm in size and 65.6%
were node-negative. In total, six interval cancer cases were detected during one year of follow-up; this is 19% of
the background incidence rate.
Conclusions: In the Tyrolean breast cancer screening program, a smooth transition from a spontaneous to an
organised mammography screening system was achieved in a short time and with minimal additional resources.
One year after introduction of the screening program, most of the quality indicators recommended by the
European guidelines had been reached.
However, it will be necessary to introduce double reading, to change the rule for BI-RADS 3, and to concentrate
on actions toward improving the participation rate.
Background
Breast cancer is the leading cause of female cancer
death in all industrialised countries (and also world-
wide), and the breast is also the leading incident cancer
site for females [1]. Therefore, screening methods for
breast cancer are of greatest public health importance.
Efficiency and efficacy of organised mammography
screening programs have been proven in large rando-
mised trials conducted in Europe and North America
[1-9]. For several years already, organised mammogra-
phy screening programs have been recommended in the
EU [2]. Austria is one of the European countries where
up to 2006 no organised programs were implemented,
but where coverage by spontaneous mammography
screening has been reported to be rather high: in a
health survey conducted in Austria in 2006-2007 more
than 80% of women aged 40+ answered that they had
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40% had had one in the past year [10]. However, it is
known that self-reporting of screening usage overesti-
mates true coverage [11], and our results are in line
with this observation comparing the 40% coverage
reported in the above-mentioned health survey to 34.5%
in our study. In 2006, the Austrian health minister
declared mammography to be one of the top health
agendas, and in July 2006 a decision was made to imple-
ment organised mammography screening programs,
namely in a first step in pilot regions, of which Tyrol is
the largest.
Two questions now arise. The first question is
whether it is really necessary to change the existing
spontaneous mammography system, and severe doubts
have been raised [12]. Up to now, our knowledge about
the performance of the existing spontaneous program is
minimal. We have only very limited information from
routine reports from the Cancer Registry of Tyrol giving
data on stage distribution of breast cancer cases on the
population level and on the time trend of breast cancer
incidence and mortality [13]. But it is well agreed that
this information is by far not sufficient to assess the
quality of a mammography program. To date most qual-
ity indices recommended by the EU guidelines cannot
be calculated because we do not have the necessary
information. It is our opinion that it is not justified to
offer a mammography screening system to healthy
women without having at least profound information on
commonly agreed quality measures.
After that, the second question is how to change the
existing screening system in the most efficient manner. It
is well accepted that there is no uniform solution for
implementing an organised screening system in a coun-
try, but, instead, when setting up the mammography sys-
tem the health system conditions in the respective
country must be given consideration. The outstanding
challenge in introducing a mammography screening pro-
gram in a country where a spontaneous screening system
was conducted for some time is whether to make a
smooth transition to an organised system or to comple-
tely redesign the existing screening system as was done,
for example, in Germany [14]. In Tyrol, a clear decision
was made to set up the new program while making best
p o s s i b l eu s eo ft h ee x i s t i n ge x p e r i e n c ea n dm a m m o g r a -
phy screening network, which was established over the
last fifteen years. Based on the latter strategy, it was pos-
sible to establish a country-wide mammography screen-
ing program in very short time. The price to be paid was
the risk of potential quality problems, because some EU
guidelines concerning the structure of the screening sys-
tem were not fully adhered to.
To our knowledge, also in Europe a number of countries
still have no organised mammography programs [15],
and therefore the experience in Tyrol can make an impor-
tant contribution to the question how to switch a health
system with spontaneous mammography screening to an
organised system that meets well-accepted quality
guidelines.
In June 2007, an organised mammography screening
program was introduced in two central counties of
Tyrol accounting for forty percent of that state’s popula-
tion. It was the aim of this study to analyse whether a
smooth change from a spontaneous to an organised
mammography system can meet the quality indicators
recommended by the EU guidelines.
Methods
Study population, invitation
The target population includes all women aged 40 to 69
living in two counties of Tyrol (i.e., the capital of
Innsbruck, and the surrounding area) and covered by
compulsory social insurance. More than 97% of the
population of Tyrol are covered by compulsory social
insurance (personal communication). All women in the
target population are sent a personal invitation letter:
women aged 40-59 annually, and women aged 60-69
biannually. All women are invited regardless of their
screening history and their individual cancer status.
Invitations are addressed directly to the women; the
invitation is to consult a screening unit. Women invited
to screening receive detailed information on the screen-
ing programme and must sign an informed consent
before screening. Mammography screening is offered by
12 screening units, nine of them run by radiologists in
private practice and three by hospital outpatient depart-
ments at the two public hospitals in the study area. The
mammogram is read by only one radiologist; ultrasound
(US) is offered to women at the radiologist’s decision.
The mammography result is coded according to the
BI-RADS [16] scheme, and the participating women are
informed of the screening result immediately after the
screening test. Women with BI-RADS 1-2 go back to
screening, women with BI-RADS 3 are invited for inter-
mediate screening in six months and women with
BI-RADS 4 or 5 are invited for further assessment.
Assessment is offered by three hospital radiology units
in the study area and includes clinical inspection, mam-
mography, US, MRI and biopsy as needed. The one
large assessment unit at Innsbruck University Hospital
works closely with a breast cancer centre. As the system
is open, women are free to contact the assessment unit
irrespective of the mammogram result, and a number of
the women go to assessment even if the mammography
result is BI-RADS 1,2,3. All program activities were
planned carefully and documented in a written protocol.
The program is directed by a screening group that
meets monthly. A subgroup of the project team is
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quarterly analysis of screening data. According to social
insurance regulations, women must first visit their gen-
eral practitioner who refers them to a screening unit.
All radiologists participating in the program had to
undergo a training program and need ÖRG (Austrian
Radiology Association) certification. In the median, pri-
vate radiologists performed 2450 mammograms and the
three hospital units 1134, 1379 and 4620 mammograms
per year. There is no waiting time for mammography.
Of the women who were referred to assessment, 64%
waited less than five working days, 18% between six and
ten working days and 19% more than ten working days.
Data collection
All mammography units register basic information in a
database. It is noteworthy that all mammograms are
registered, not only those for women belonging to the
target population. Due to data privacy restrictions,
women must sign a written consent to permit data
transfer to the screening database; if a woman refuses
consent, an empty dataset marked simply “data transfer
declined” is sent to the mammography database. Screen-
ing information is transferred to the screening database
after pseudonymising the woman’ss o c i a li n s u r a n c e
number. The pseudonymisation process permits linkage
of data for a specific woman coming from different
units and guarantees data confidentiality, because the
pseudonymisation process can be reversed only within
the screening unit. An analogous procedure was estab-
lished for assessment units. Finally, data on tumour
characteristics are collected by the Cancer Registry of
Tyrol. The Cancer Registry has developed a network of
various data sources that guarantees a high degree of
completeness and validity of cancer data in the popula-
tion of Tyrol. Details on registry procedures and figures
on completeness have been reported elsewhere [17].
The Cancer Registry also collects each patient’ss o c i a l
insurance number and, consequently, Cancer Registry
data can be linked to the screening database by applying
the same pseudonymisation process. Cancer Registry
data enable us to analyse data on tumour characteristics
(e.g., tumour size, lymph node status, information on
surgery) and to assess interval cancer cases.
Participation rate should reflect all women undergoing
a screening mammography. Part of them refuse consent
to permit data transfer. In order to account for these
women, we estimated the proportion of all women
denying consent and belonging to age group 40-69 as
being 56% of 5.8%, namely 3.2%. Thus, the estimated
participation rate is equal to the observed participation
rate plus 3.2%. Finally, invitation data are provided by
the invitation system run by the social insurance carrier.
Invitation data are transferred to the screening database
as aggregated numbers of invited women per month of
invitation, age group (five-year age classes) and county.
Recall is defined as call for further assessment or invita-
tion to intermediate screening within six months.
Statistical analysis
Plausibility checks are implemented both at the mam-
mography and the assessment unit level and at the cen-
tral screening database level.
The screening database is realised as STATA data-
sets. Linkage between screening data, assessment data
and Cancer Registry data is based on the pseudonym
number. We report numbers and proportions as
defined in the EU guidelines. For some indices, popu-
lation-based rates are computed using the official
population data supplied by Statistics Austria. No sta-
tistical testing is applied. All reporting is done with
STATA Version 9 [18].
Spontaneous mammography screening was introduced
in Tyrol already in the early 1990 s. Thus, the underly-
ing background incidence is defined by years 1988-1990,
see Table 1.
This study was conducted in conformity to the
Helsinki Declaration [19]. The project was approved by
the Ethics Committee of Medical University Innsbruck.
Results
From June 2007 to May 2008, 56,432 women in the tar-
get population were invited, 40.3% in age group 40-49,
31.1% in age group 50-59 and 28.6% in age group 60-69,
see Table 2. A total of 1,188 invitation letters were
returned as undeliverable. Because of their small num-
ber, we did not take the returned invitations into con-
sideration for analysis. After deleting N = 80 cases
without a BI-RADS classification, we ended up with
17,645 screening cases in the analysis dataset. Of the
screening cases 40.4% were in age group 40-49, 32.2% in
age group 50-59 and 27.4% in age group 60-69.
Table 1 Breast cancer incidence rate in Tyrol before
spontaneous screening program 1988-1990 (background
incidence) and before changing the screening system
2005-2007
40-49
1) 50-59
1) 60-69
1) Total (40-69)
1)
1988-1990
Breast Cancer 52 (128.8) 54 (176.0) 74 (244.0) 180 (177.5)
Invasive 50 (123.8) 53 (172.7) 72 (238.5) 175 (172.9)
In situ 2 (5.0) 1 (3.3) 2 (5.5) 5 (4.6)
2005-2007
Breast Cancer 82 (146.2) 87 (206.3) 96 (263.0) 265 (196.5)
Invasive 74 (132.0) 79 (187.3) 89 (245.6) 242 (179.9)
In situ 8 (14.2) 8 (19.0) 7 (17.4) 23 (16.6)
1)Average number of incident cases per year and age-specific rate per 100,000.
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low-up was 31.3%; after correcting for women declining
data transfer to the screening database, the overall parti-
cipation rate was 34.5% (34.5%, 35.7% and 33.1% in age
groups 40-49, 50-59 and 60-69, respectively). After com-
pleting a second year of follow-up (end of observation
was 31 May 2009), 55.5% of the invited women had
undergone at least one screening examination, with a
higher participation rate in younger age classes (57.5%,
56.7% and 51.4% for age groups 40-49, 50-59 and 60-69,
respectively), see Table 2.
Screening outcome was negative for 96.6%; 1.6% of
cases were recommended for intermediate mammogra-
phy (six months) after screening (1.2% in age group
60-69), 1.8% were referred for further assessment (1.4%
in age group 60-69) and in 10 cases the screening out-
come was unknown (Table 3).
According to screening policy, the screening radiolo-
gists were free to perform additional US. The reason for
additional US was recorded as breast density grades
according to the American College of Radiology (ACR)
3 or 4 in 37.6%, equivocal findings on mammography in
16.9%, and other nonspecified reasons in 45.5% of cases.
Overall, 83.3% of women had an additional US examina-
tion, with clear differences between the age groups: the
proportions were 89.2%, 81.3% and 77.1% in age groups
40-49, 50-59 and 60-69, respectively (Table 4).
Of 315 assessments performed, 38.4% had a core
biopsy (45.5% in age group 60-69), 7.6% a fine needle
biopsy and 1.9% (six cases) an open biopsy. This means
that of 1000 women screened, nine had a biopsy (8 in
age group 60-69) and 0.3 underwent an open biopsy
(Table 5). Of all assessments 75.6% were negative, 2.9%
were recommended for intermediate screening and in
68 (21.6%) screening cases breast cancer was diagnosed
(12.9%, 20.2% and 42.4% in age groups 40-49, 50-59 and
60-69 respectively), see Table 6.
For all fine needle biopsies, the diagnosis was benign.
The positive predictive value of core biopsy was 50.4%
in total and 35.3%, 47.5% and 80.0% in age groups
40-49, 50-59 and 60-69, respectively. The six open biop-
sies showed two benign and four malignant cancer cases.
Of the 68 breast cancer cases, 61 were invasive, and
seven were ductal carcinoma in situ. The cancer detec-
tion rate was 3.9 per 1000 mammograms in total and
2.5, 3.9 and 5.8 in age groups 40-49, 50-59 and 60-69
respectively, see Table 6.
Of all invasive cancers detected, 34.4% were less then
10 mm in size and 65.6% were node-negative, without
differences for age group, see Table 7.
After linking screening data and Cancer Registry data
(only depseudonymised data), we observed a total of
six interval cancer cases within one year after screen-
ing, four in age group 40-49, one in age group 50-59
and one in age group 60-69. The interval cancer rate
was 34 per 100,000 mammograms; this is 19% of the
underlying background incidence rate (defined by years
of diagnosis 1988-1990). Details are shown in Table 8,
which shows the most important quality indicators
defined in the EU guidelines restricted to age group
50-69, because EU recommendations are given for that
age group.
Table 2 Invitation system: Number of women invited, number of mammograms performed (numbers and age
percentages)
40-49 50-59 60-69 Total (40-69)
Women invited 22739 17531 16162 56432
Number of screens in first year 7124 5689 4832 17645
Observed participation rate in first year 31.3% 32.5%
Estimated participation rate in first year
1) 34.5% 35.7%
Cumulative participation rate after two years
2) 54.3% 53.5% 48.2% 52.3%
Estimated cumulative participation rate after two years
1) 2) 57.5% 56.7% 51.4% 55.5%
1)Also a part of women age 40-59 go to mammography screening at a two year interval.
Table 3 Screening outcome
40-49 50-59 60-69 Total
Negative 6853 (96.2%) 5482 (96.4%) 4704 (97.4%) 17039 (96.6%)
Intermediate screening test following screening 125 (1.8%) 95 (1.7%) 57 (1.2%) 277 (1.6%)
Assessment
Recommended 142 (2.0%) 109 (1.9%) 68 (1.4%) 319 (1.8%)
Performed 140 (2.0%) 109 (1.9%) 66 (1.4%) 315 (1.8%)
Unknown
1) 4331 0
Total 7124 5689 4832 17645
1)BI-RADS 0 without assessment was treated as unknown.
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We analysed the situation after a first year of introdu-
cing organised mammography screening in two counties
in Tyrol accounting for 40% of that state’sp o p u l a t i o n .
The organised program was established in a smooth
transition from the existing spontaneous mammography
screening system, namely by introducing a written pro-
tocol, a personal invitation system, a training program,
and by setting up a screening database allowing us to
investigate performance and outcome parameters in
detail. Although not all EU recommendations have been
followed to date, most quality indicators are in the
range of accepted and/or desired levels given by the EU
guidelines: the proportion of cases called for further
assessment (20 per 1000 mammograms), the biopsy rate
(9 per 1000 mammograms), the proportion of invasive
screening-detected cancer (89.7%), the proportion of
invasive cancer ≤ 10 mm in size (34.4%) and the interval
cancer rate expressed as a multiple of the background
incidence rate (19%). The average number of screens
read by a radiologist (about 2400) does not meet the EU
recommendation of 5000. However, in about four of five
w o m e na na d d i t i o n a lU Si sd o n e ,w h i c hi sk n o w nt o
improve the sensitivity of the screening test, see for
example [20,21].
Some of the parameters are near the value expected in
subsequent screening rounds and not in a first round
(for example, recall rate and breast cancer detection
rate). However, we must remember that the organised
program was introduced after fifteen years of the spon-
taneous screening program. Some indicators like pro-
portion of stage II+ cancers and node-negative cancer
are slightly outside the EU-accepted levels. Some of the
observations could be due to small numbers (we
observed a total of 68 cancer cases). So it is too early to
come to final conclusions on the mammography screen-
ing model we describe here.
Only one indicator clearly misses the EU recommen-
dations, namely the participation rate. However, partici-
pation rate depends not only on program organisation,
but also on cultural background. A look at neighbouring
German-speaking countries, which should have a similar
culture, shows participation rates of 54% in Germany
[14] and 25.9% to 65.9% in five cantons of Switzerland
[22]. Thus, a cumulative participation rate of 55% in the
first two years would seem to be rather successful by
comparison to that of countries with a similar cultural
background, albeit not the goal we aimed for.
Among the strengths of the Tyrolean breast cancer
screening program is its implementation: within a short
time and with minimal additional resources it was possible
to set up an organised population-based screening pro-
gram that - at least at evaluation after one year - met all of
the EU quality indicators except participation rate. It was
not necessary to set up extra screening units; instead, the
program used the existing network of screening and
assessment units. In terms of epidemiology, another of the
program’s strengths is a complete pseudonymised database
Table 4 Additional ultrasound imaging at screening
40-49 50-59 60-69 Total
Ultrasound added to mammography screening 6358 (89.2%) 4624 (81.3%) 3723 (77.1%) 14705 (83.3%)
Reason for ultrasound:
Breast density (ACR 3/4) 2855 (44.9%) 1638 (35.4%) 1041 (28.0%) 5534 (37.6%)
Equivocal finding 1037 (16.3%) 810 (17.5%) 635 (17.1%) 2482 (16.9%)
Other 2466 (38.8%) 2176 (47.1%) 2047 (55.0%) 6689 (45.5%)
Table 5 Assessment procedure
40-49 50-59 60-69 Total
Additional imaging
Ultrasound 140 (100%) 106 (97.2%) 61 (92.4%) 307 (97.5%)
MRI 24 (17.1%) 21 (19.3%) 21 (31.8%) 66 (21.0%)
Biopsy 63 (45.0%) 51 (46.8%) 37 (56.1%) 151 (47.9%)
Core biopsy 51 (36.4%) 40 (36.7%) 30 (45.5%) 121 (38.4%)
Fine needle biopsy 10 (7.1%) 10 (9.2%) 4 (6.1%) 24 (7.6%)
Open biopsy 2 (1.4%) 1 (0.9%) 3 (4.5%) 6 (1.9%)
Biopsy rate per 1000 mammograms 8.8 9.0 7.7 8.6
PPV for core biopsy
1) 35.3.4% 47.5% 80.0% 50.4%
PPV for open biopsy
2) 66.7%
Total 140 109 66 315
1)For all fine needle biopsies the result was benign.
2)For six open biopsies two were benign and four malignant. Because of small numbers, PPV is shown only for the total.
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the Cancer Registry data. The database was set up in a
very short time, it is up to date within one month and
serves as a very important tool for monitoring the pro-
gram quality indicators or, more generally speaking, for all
kinds of quality assurance tasks.
Nevertheless, the program differs from many orga-
nised programs in the EU in three aspects. Firstly, we
also included women aged 40-49. During previous spon-
taneous screening campaigns women aged 40-49 were
officially invited to participate in mammography screen-
ing. The discussion in the USA after publishing the
revised recommendation by USPSTF [23,24] shows that
it is very challenging and difficult for women to under-
stand why a service is cancelled that was recommended
for several years. Without well founded data, we feel it
is not justified to discontinue screening in age class
40-49. We are collecting detailed data and will evaluate
the goods and harms [23,25] in coming years. In addi-
tion, the analysis of breast cancer mortality in Tyrol in
the past decade shows that mortality decrease was great-
est in women aged 40-49, an effect that can at least
partly be attributed to spontaneous screening [13].
Secondly, we offer breast US as an additional diagnos-
tic tool in screening. In opportunistic screening in
Tyrol, US was offered to women with dense breasts
(ACR density grades 3 and 4) and with inconclusive
findings on mammography [26,27]. The line of reason-
ing concerning screening in age group 40-49 also holds
for adjunct US, bearing in mind that adjunct US was
offered during the last decade. It has been shown by
various authors that the additional use of US can
improve cancer detection rates, especially in younger
women and women with dense breasts [20,21,26]. The
relative percentage of carcinomas found in supplemental
breast US examinations as a fraction of the total number
of detected cancers was reported by four studies with a
mean percentage of 22.5% (15%-34%) [19]. In the second
year of the organised program we collected detailed data
allowing us to analyse the contribution of US to sensi-
tivity and specificity outside the framework of studies,
namely in a population-based setting.
And thirdly, we were not able to implement double
reading during the piloting phase. Interestingly, perfor-
mance parameters, especially interval cancer rate,
showed that also without double reading an acceptable
quality level was achieved. The question of the comple-
teness of interval cancer rate depends on the complete-
ness of the Cancer Registry of Tyrol, which covers the
target population. We analysed quality measures for the
Cancer Registry in detail, also completeness, and found
a high degree of completeness, both for all cancer sites
and for breast cancer [17]. Therefore, we think it is unli-
kely that we missed interval cancers. However, the num-
bers are small and we cannot exclude the possibility that
we missed one or two cases, which would mean a 33%
increase in the interval cancer rate (from 6 to 8 cases).
Clearly, a longer observation period is necessary before
Table 6 Assessment outcome
40-49 50-59 60-69 Total
Negative 117 (83.6%) 85 (78.0%) 36 (54.5%) 238 (75.6%)
Recommendation for intermediate screening after assessment 5 (3.6%) 2 (1.8%) 2 (3.0%) 9 (2.9%)
Breast cancer 18 (12.9%) 22 (20.2%) 28 (42.4%) 68 (21.6%)
In situ 4 (2.9%) 2 (1.8%) 1 (1.5%) 7 (2.2%)
Invasive 14 (10.0%) 20 (18.3%) 27 (40.9%) 61 (19.4%)
Breast cancer detection rate per 1000 mammograms 2.5 3.9 5.8 3.9
Ratio screening breast cancer detection rate vs. background incidence rate
1) 1.9 2.2 2.4 2.2
Total 140 109 66 315
1)Background incidence rate: see Table 1.
Table 7 Characteristics of invasive cancers
40-49 50-59 60-69 Total
Tumour size (mm): 13.5; 3-50 14; 2-60 12; 1-49 13; 1-60
Median; range
Tumour size (mm):
<= 10 mm 6 (42.9%) 6 (30.0%) 10 (37.0%) 21 (34.4%)
11-20 mm
1) 6 (42.9%) 8 (40.0%) 12 (44.4%) 26 (42.6%)
>20 mm 3 (21.4%) 6 (30.0%) 5 (18.5%) 14 (23.0%)
Lymph node
involvement
5 (35.7%) 7 (35.0%) 9 (33.3%) 21 (34.4%)
Total 14 20 27 61
Tumor stage
according to TNM
pT1 12 (85.7%) 14 (70.0%) 22 (81.5%) 48 (78.7%)
pT2 2 (14.3%) 5 (25.0%) 5 (18.5%) 12 (19.7%)
pT3 1 (5.0%) 1 (1.6%)
pN0 9 (64.3%) 13 (65.0%) 18 (66.7%) 40 (65.6%)
pN1 4 (28.6%) 4 (20.0%) 6 (22.2%) 14 (23.0%)
pN2 1 (7.1%) 2 (10.0%) 2 (7.4%) 5 (8.2%)
pN3 1 (5.0%) 1 (3.7%) 2 (3.3%)
M0 13 (92.9%) 19 (95.0%) 26 (96.3%) 58 (95.1%)
M1 1 (7.1%) 1 (5.0%) 1 (3.7%) 3 (4.9%)
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observation could in part be explained by short screen-
ing intervals in the age group 40-59 and by the use of
additional US. Nevertheless, double reading will be
introduced in the regular screening program after con-
cluding the piloting phase.
Also, as we do not have a scheduling system, women
are invited to consult the screening unit at any time
that is convenient to them. The time when the invita-
tion is sent is independent of a woman’si n d i v i d u a l
screening history. The latter point is corrected in the
next invitation round, which required a change in the
written consent for reasons of data privacy.
Many countries have had a mammography screening
program running for decades or for a shorter time. On
the other hand, six EU member states still have no orga-
nised nationwide breast cancer screening program, and
in seven member states a nationwide rollout was in
2007 [15]. What can be learned from our experience by
countries that are thinking of introducing or are already
in the process of planning to introduce a mammography
screening program? In our opinion, the greatest differ-
ence between our approach and many other approaches
is the smooth transition made from the existing sponta-
neous program to organized population-based screening.
We made use of the network of screening and assess-
ment units that had already been set up during sponta-
neous screening. What we added was an invitation
system covering the entire population of Tyrol, a screen-
ing database that allows quality indices to be monitored
and a well-defined training program for both screening
and assessment units. With this strategy we were able to
meet most EU quality indices in a very short time.
Conclusions
A smooth transition from a spontaneous to an organised
mammography screening syst e mt h a tu s e st h ee x i s t i n g
screening units, introduces an invitation system and a
quality assurance program (including a screening data-
base) can meet the quality indicators recommended by
European guidelines in a short time and with minimal
additional resources. However, it will be necessary to
introduce double reading, to change the rule for
BI-RADS 3 and to concentrate on actions toward
improving the participation rate.
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